08 March 2022 | News
The panel screens for all 20 high and moderate risk non-BRCA genes associated with hereditary breast and ovarian cancer
Image credit: Shutterstock
LifeCell has launched a breast screen panel, a comprehensive genetic screening test that assesses the risk of breast cancer in women.
LifeCell’s breast screen panel not only screens for the mutations in the most common BRCA1 and BRCA2 genes but also screens for all 20 high and moderate risk non-BRCA genes associated with hereditary breast and ovarian cancer as outlined by the National Comprehensive Cancer Network (NCCN) guidelines. Additionally, the panel utilises next-generation sequencing which not only offers higher throughput, coverage (including deletion and duplication), and speed but also higher accuracy than other predictive tests.